)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Disruptive Pharma
Disruptive Pharma (DPHA) investor relations material
Disruptive Pharma Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary20 Aug, 2026
Executive summary
Q2 2026 marked a strategic shift with the completion of a reverse takeover, transitioning focus to the Formulite® platform for next-generation drug development and commercialization.
Financials for the period reflect the legacy Guard Therapeutics business, not the new Disruptive Pharma operations.
Formulite® is positioned as a patented, clinically validated technology aimed at improving solubility, stability, and bioavailability of oral drugs.
The business model is partner-driven, targeting collaborations, licensing, and milestone/royalty revenues.
Financial highlights
Net sales were 0 KSEK for both Q2 and H1 2026 (unchanged year-over-year).
Net result for Q2: -4,364 KSEK (improved from -32,221 KSEK year-over-year); H1: -10,716 KSEK (improved from -66,436 KSEK year-over-year).
EPS for Q2: -0.22 SEK (vs. -1.66); H1: -0.53 SEK (vs. -4.19).
Cash and equivalents at June 30: 34,105 KSEK (down from 100,481 KSEK year-over-year).
Equity at period end: 32,178 KSEK (vs. 80,395 KSEK prior year).
Outlook and guidance
The company expects its financial resources post-transaction to support operations and strategic investments for approximately 18 months, even without revenues.
Focus is on expanding Formulite® projects, scaling manufacturing, and establishing strategic partnerships.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Disruptive Pharma
- Q1 loss narrowed, cash reserves rose, and delisting looms pending strategic alternatives.DPHA
Q1 2026 - RMC-035 program ended after negative trial; strategic review and cost cuts underway.DPHAQ4 2025
- Negative POINTER study results prompt strategic review and development pause.DPHAQ3 2025
- Phase 2b POINTER showed no significant kidney benefit for RMC-035, prompting strategic review.DPHAStudy Result
- Phase 2b POINTER study recruitment completed early; positive safety review and SEK 120M raised.DPHAQ2 2025
- Phase 2b POINTER study underway; RMC-035 targets $1B+ global market in cardiac surgery.DPHAQ3 2024
- Regulatory progress and new funding position Guard Therapeutics for key clinical milestones.DPHAQ2 2024
- Q1 saw rapid clinical progress and SEK 120m in new funding, despite a widened loss.DPHAQ1 2025
- Net loss widened as R&D ramped up for POINTER; major capital raise planned for 2025 milestones.DPHAQ4 2024
Next Disruptive Pharma earnings date
Q3 202612 Nov, 2026
Disruptive Pharma
Next Disruptive Pharma earnings date
Q3 202612 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Disruptive Pharma AB is a Swedish biopharmaceutical company focused on the development of therapies for the diagnosis and treatment of acute kidney injuries. The company is most known for its investigational drug, ROSGard, a biological candidate designed to prevent kidney damage by mimicking the body's defense system against oxidative stress, thereby protecting, cleaning, and repairing exposed cells and tissues. Guard Therapeutics is headquartered in Stockholm, Sweden, and its shares are listed on the Nasdaq First North.